1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Avisa Diagnostics Inc.

Avisa Diagnostics Inc.

FOGCF
Avisa Diagnostics Inc.US flagOther OTC
0.00
USD
- -
- -
97,176.00Market Cap
Avisa Diagnostics Inc.
FOGCF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.05
0.17
0.05
- -
Revenue per Share
-678.26
-304.32
-295.94
-210.84
-161.93
-24.95
-4.19
6.57
-1.25
-0.02
-1.56
-0.84
-0.14
-0.3
Basic EPS, GAAP
-615.34
-289.02
-257.04
-220.17
-65.78
-4.19
-3.22
-0.39
-0.77
-0.02
-0.54
-0.28
-0.09
-0.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-814.92
-681.36
-893.46
-991.07
-792.18
-492.92
-450.08
-330.93
-286.81
-0.02
0.93
-0.05
-0.18
-0.26
Book Value per Share
581.4
313.28
314.89
205.33
29.52
-5.71
-10.53
-0.52
-1.7
-0.02
0.41
0.03
-0.1
-0.07
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
4
5
5
12
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3,079.76
-315.93
-251.65
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
Depreciation Expense
-4
-3
-5
-4
-5
-1
- -
- -
- -
- -
-6
-4
-1
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3,342.17
-492.8
-257.63
- -
Profit Margin (%)
- -
-1
3
- -
- -
- -
-1
- -
- -
- -
2
- -
- -
-3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
LT Debt
4
4
6
4
1
- -
-1
- -
- -
- -
4
- -
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-1.79
- -
- -
- -
- -
- -
-10.39
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
ST Debt
- -
6
- -
LT Borrowings
- -
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
3
Market Capitalization
- -
2
4

Working Capital

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
24
3
Payables & Accruals
- -
3
3
ST Debt
- -
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-668.44%
-1,288.56%
-414.86%
Free Cash Flow
372.8%
796.42%
-67.09%
Net Income, GAAP
795.91%
1,677.7%
-82.69%
Sales/Revenue/Turnover
- -
- -
-66.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
1
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-0.13
-0.14
-0.11
- -
-0.84
2020
-0.02
-0.07
-0.23
- -
-0.14
2021
0.52
-0.14
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
Similar Companies
PharmaResearch Co., Ltd. (214450.KQ)
Noveris Health Sciences Inc. (MYCOF)
Recordati S.p.A. (RCDTF)
Chemo Pharma Laboratories Limited (CHEMOPH.BO)
MedPlus Health Services Limited (MEDPLUS.NS)
Fredun Pharmaceuticals Limited (FREDUN.BO)
Business
Avisa Diagnostics Inc. is a medical diagnostics company specializing in the development and commercialization of rapid, point-of-care diagnostic tests focused primarily on infectious diseases. The company’s core products include proprietary rapid antigen and antibody tests designed to deliver quick, accurate results for conditions such as influenza, COVID-19, and sexually transmitted infections. Their offerings encompass product categories such as lateral flow immunoassays and molecular diagnostics, which are employed in clinical settings, urgent care centers, and other healthcare environments. Founded in 2018 and headquartered in Cambridge, Massachusetts, Avisa Diagnostics operates primarily in the United States with expanding interests in international markets. The company serves healthcare providers, clinics, and laboratories by providing diagnostic solutions that emphasize ease of use, speed, and reliability. Avisa Diagnostics integrates innovative biotechnology approaches to develop point-of-care platforms that facilitate better patient management and improved public health outcomes. In the past 1-2 years, Avisa Diagnostics has made significant strategic advancements including expanding its product portfolio with new rapid test launches targeting broader infectious disease detection. It has also formed key partnerships with healthcare organizations to scale distribution and enhance technological integration in diagnostics. Additionally, the company has pursued business growth initiatives like funding rounds and potential acquisitions to accelerate research and commercialization efforts. These recent developments reflect Avisa Diagnostics’ commitment to strengthening its position in the competitive diagnostics industry while responding dynamically to evolving healthcare needs.